Shares of Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) leaped 46 cents to close at $1.61 after the FDA allowed the company to move forward with late-stage study of its cancer drug candidate.
Keryx Moves Forward With Study
August 03, 2009 at 16:46 PM EDT
